Table 4.

Clinical follow-up

No. of patients
Follow-up available21/23 (91.3%)
Treatment
    steroids19/21 (90.5%)
    cyclophosphamide14/21 (66.7%)
        intravenous2/21 (9.5%)
        oral12/21 (57.1%)
    plasmapheresis5/21 (23.8%)
Patients on HD at presentation11/23 (47.8%)
    remain on HD8/11 (72.7%)
    transiently discontinued HD1 (9%)
    came off HD2 (18.2%)
        final serum creatinine (mg/dl)3.25 (3.0–3.5)
        duration of follow-up (mo)7 (4–10)
Patients not on HD at presentation with available follow-up10/21 (47.6%)
    became HD-dependent3/10 (30%)
        duration of follow-up until HD (mo), mean (range)4.5 (1–8)
    remain off HD7/10 (70%)
        duration of follow-up (mo)9.3 (0.25–25)
        final serum creatinine (mg/dl)2.26 (1.4–3.4)
Patient status
    duration of follow-up (mo)14.6 (0.25–92)
    alive10/21 (47.6%)
    alive post-renal transplant3/21 (14.3%)
    died8/21 (38.1%)
        time from biopsy to death (mo)6.1 (0.25–25)
  • HD, hemodialysis. Data are mean with range or fraction with corresponding percentage.